307 results about "Myoma" patented technology

A first method for ultrasound uterine medical treatment includes obtaining an end effector having an ultrasound medical-treatment transducer assembly, identifying a blood vessel which supplies blood to a portion of the uterus, and medically treating the blood vessel with ultrasound from the transducer assembly to substantially seal the blood vessel to substantially stop the supply of blood from the blood vessel to the portion of the uterus. In one example, shrinkage of a uterine fibroid is accomplished through use of the end effector endoscopically inserted into the uterus. A second method for ultrasound uterine medical treatment includes endoscopically inserting the end effector into the uterus and medically treating the endometrium lining with ultrasound from the transducer assembly to ablate a desired thickness of at least a portion of the endometrium lining to substantially stop abnormal uterine bleeding from the endometrium lining.

A method for medically employing ultrasound within a body cavity of a patient. An end effector is obtained having a medical ultrasound transducer assembly. A biocompatible hygroscopic substance is obtained having a non-expanded anhydrous state and having an expanded and fluidly-loculated hydrated state. The end effector, including the transducer assembly, and the substance in substantially its anhydrous state are inserted into a body cavity (such as endoscopically inserted into a uterus) of a patient. The transducer assembly is used to medically image and / or medically treat patient tissue (such as stopping blood flow to, and / or ablating, a uterine fibroid). A system for medically employing ultrasound includes the end effector and the substance. In another system, the end effector includes the substance. The substance in its hydrated state expands inside the body cavity providing acoustic coupling between the wall of the body cavity and the transducer assembly.

The invention is a transvaginal ultrasound probe having an attached echogenic needle that is useful in the treatment of uterine fibroids. The echogenic needle has an echogenic surface near its tip that allows the physician to visualize its location using ultrasound imaging. In one embodiment, the needle has an active electrode at its distal end. The active electrode supplies radio frequency energy to a fibroids causing necrosis of the targeted fibroid or by destroying the fibroid's vascular supply. The radio frequency needle preferably has a safety device that shuts-off energy if the needle punctures the uterine wall. In a second embodiment, the needle has a cryogen supply tube and cryogen supply. This embodiment destroys fibroid tissue by freezing it or its vascular supply when the tissue comes in contact with the needle's frozen distal end. The invention further includes the method of using the ultrasound probe with the attached needle.

The invention is directed to an intravaginal staple for occluding a female patient's uterine artery in the treatment of a uterine disorder such as fibroids, DUB, PPH, uterine bleeding after caesarian delivery and the like. The intravaginal staple includes an occluding bar having a pressure applying surface and at least one and preferably two tissue penetrating legs which are provided with protuberances which help to retain the staple leg within the penetrated tissue. At least part of the staple is preferably formed of bioabsorbable material so that it will in part self destruct at a preselected time period by separation of staple components caused by the bioabsorption of a bioabsorbable portion of the staple. The staple deployment system may be provided with elongated handles and staple deploying mechanisms on the distal ends of the handles to drive the legs of the staple into the tissue bundle about the uterine artery so that pressure applied by the occlusion bar occludes the uterine artery.

A surgical fluid management system delivers fluid for distending a uterine cavity to allow cutting and extraction of uterine fibroid tissue, polyps and other abnormal uterine tissue. The system comprises a fluid source, fluid deliver lines, one or more pumps, and a filter for re-circulating the distension fluid between the source and the uterine cavity. A controller can monitor fluid retention by the patient.

The present invention relates to apparatus and methods for thermally ablating uterine fibroids. More particularly, the present invention relates to a conduit having a plurality of channels for delivering a plurality of thermal ablation probes to an organic target such as a uterine fibroid, the probes being delivered in such configuration and orientation as to enable efficient and thorough ablation of the fibroid. In a preferred embodiment, the conduit is formed as a sleeve having a large central lumen sized to accommodate a hysteroscope, channels sized to accommodate cryoprobes are used as thermal ablation probes, and comprises thermal insulation materials serving to protect the cervix from damage by cold. The present invention further relates to bent cryoprobes usable in conjunction with such a conduit and designed to exit therefrom in a desired configuration useful for ablating a large fibroid.

The invention is a transvaginal ultrasound probe having an attached echogenic needle that is useful in the treatment of uterine fibroids. The echogenic needle has an echogenic surface near its tip that allows the physician to visualize its location using ultrasound imaging. In one embodiment, the needle has an active electrode at its distal end. The active electrode supplies radio frequency energy to a fibroids causing necrosis of the targeted fibroid or by destroying the fibroid's vascular supply. The radio frequency needle preferably has a safety device that shuts-off energy if the needle punctures the uterine wall. In a second embodiment, the needle has a cryogen supply tube and cryogen supply. This embodiment destroys fibroid tissue by freezing it or its vascular supply when the tissue comes in contact with the needle's frozen distal end. The invention further includes the method of using the ultrasound probe with the attached needle.

A method and apparatus for treatment of diseases of a breast, fallopian tube and female reproductive organs by injecting / delivering a treatment substance / chemo-gel, directly into the target tissue of the body organ, and thereby leaving the remaining body organs relatively unaffected. Specific formulations and composition of treatment substances are provided. The typical treatment substance / chemo-gel formulations contain at least two principle components including an active treatment (therapy) substance, and an inactive binding (carrier) substance for thickening the treatment substance. Specific substance formulations are provided, including a range of recommended dosage levels for optimum treatment of a specific disease of a female reproductive organ. Injection / delivery apparatus and methods, and apparatus for guiding its placement are also provided.

A high-power ultrasound heating applicator for minimally-invasive thermal treatment of uterine fibroids or myomas. High-intensity interstitial ultrasound, applied with minimally-invasive laparoscopic or hysteroscopic procedures, is used to effectively treat fibroids within the myometrium in lieu of major surgery. The applicators are configured with high-power capabilities and thermal penetration to treat large volumes of fibroid tissue (>70 cm3) in short treatment times (3-20 minutes), while maintaining three-dimensional control of energy delivery to thermally destroy the target volume.

The present invention relates to a combination of resveratrol with progestogen, and medicaments and pharmaceutical compositions containing the same, which are useful in the treatment and / or prevention of myoma and / or endometriosis, providing their size reduction and the control of related symptoms. Said association may additionally comprise an estrogen component. A treatment method and a kit are also objects of this invention.

Non-permanent occlusion of the uterine arteries is sufficient to cause the demise of uterine myomata without unnecessarily exposing other tissues and anatomical structures to hypoxia attendant to prior permanent occlusion techniques. A therapeutically effective transient time of occlusion of a uterine artery to treat uterine fibroid tumors is from 1 hours to 24 hours, and preferably is at least about 4 hours. A therapeutically effective temporary time of occlusion of a uterine artery to treat uterine fibroid tumors is from 1 day (24 hours) to 7 days (168 hours), and preferably is about 4 days (96 hours). By invaginating the tissues of the vaginal wall up to or around a uterine artery, collapse of the uterine artery can be achieved without penetrating tissue of the patient.

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.

The present compounds are intermediates for the preparation of quinoline derivatives and compositions having gonadotropin-releasing hormone antagonistic activity useful as propylactics or therapeutic agent for the prevention or treatment of several hormone dependent diseases, for example, a sex hormone dependent cancer (e.g. prostatic cancer, uterine or cervical cancer, breast cancer, pituitary adenoma), benign prostatic hypertrophy, myoma of the uterus, endometriosis, precocious puberty, amenorrhea, premenstrual syndrome, polycystic ovary syndrome and acne vulgaris; are effective as a fertility controlling agent in both sexes (e.g. a pregnancy controlling agent and a menstrual cycle controlling agent); can be used as a male or female contraceptive, as an ovulation-inducing agent; can be used as an infertility treating agent by using a rebound effect owing to a stoppage of administration thereof; and are useful for modulating estrous cycles in animals in the field of animal husbandry, as agents for improving the quality of edible meat or promoting the growth of animals, and as agents for promoting spawning in fish.

The invention discloses a novel traditional Chinese medicinal composition for treating ovarian cyst and a preparation method thereof. The traditional Chinese medicinal composition mainly comprises the following raw material medicines: pangolin scales, tribulus terrestris, spina gleditsiae, rhizoma sparganii, zedoary, leech, ground beeltle, aspongopus, dragon's blood, Chinese trumpet creeper, cowherb seed, suberect spatholobus stem, twotooth achyranthes root, motherwort herb, peach kernel, red flower, szechuan lovage rhizome, immature bitter orange, szechwan chinaberry fruit, pseudoginseng root, cyperus rotundus, Chinese eaglewood and the like. The traditional Chinese medicinal composition can be prepared into any common oral preparation according to the conventional traditional Chinese medicinal preparation method, can obviously improve abnormal menstruation caused by myoma of uterus, colporrhagia, increased leucorrhea, abdomen bilge pendant, abdominal pain, frequent micturition and urination disorder due to myoma pressure on the bladder, constipation and impeded defecating due to myoma pressure on the rectum and other symptoms, and has the advantages of obvious inhibition of cyst hyperplasia, prevention of cancerization, exact clinical curative effect, obvious curative effect, quick response, low cost, fundamentally no toxic or side effect, and the like.

A method of ablating a uterine fibroid using a particular trocar is disclosed. The trocar comprises a plurality of ablation stylets mounted for movement from within the trocar to positions extending from the trocar. The trocar is adjustable to assume a plurality of configurations, each of the configurations having the stylets extended to a different extent from the trocar. A region to be ablated is imaged. The region may correspond to all or a portion of a uterine fibroid. The size of the region to be ablated is noted. The size of the region to be ablated is compared to a matrix of known ablation regions, each of the known ablation regions being associated with one of the configurations of the particular trocar, and each of the known ablation regions being associated with a position of the trocar relative to the known ablation region. The region to be ablated is associated with a most nearly matching known ablation region by comparison of the region to be ablated to the known ablation regions. A trocar of the design of the particular trocar is inserted into the uterine fibroid at a position, with respect to the region to be ablated, which more closely matches the position of the particular trocar with respect to the known ablation region. The stylets are deployed from the trocar to an extent corresponding to the configuration associated with the most nearly matching known ablation region.

A method for treating a uterine fibroid comprises forming an incision in a vaginal fornix to expose a first blood vessel supplying the fibroid, forming an opening in the first blood vessel and inserting an introducer into the first blood vessel via the opening in combination with the steps of advancing a catheter to a desired position within the first blood vessel via the introducer and introducing an occlusive agent into the first blood vessel through the catheter to block blood flow through the first blood vessel. A device for treating uterine fibroids comprises an elongated sheath sized for insertion into uterine arteries via an incision in the vaginal fornix, the sheath including a sheath lumen extending from a first sheath opening formed in a proximal end of the sheath to a second sheath opening formed in a distal end of the sheath and a body a distal end of which is connected to the proximal end of the sheath, the body including a body lumen extending therethrough from a first body opening at a proximal end of the body and a second body opening at the distal end thereof, the second body lumen communicating with the sheath lumen in combination with a hemostatic valve controlling the flow of blood through the body lumen.

Devices and methods are disclosed for treating a uterine disorder which receive its blood supply from a uterine artery. In particular, uterine fibroids are effectively treated by occluding the uterine arteries using trans-vaginal, trans-uterine, transrectal, or retroperitoneal approaches. The devices and methods are advantageous because the inventive procedures may be performed by a patient's gynecologist in the course of treatment, avoiding the need for referrals to specialist practitioners and for more radical treatments, such as hysterectomies. The methods include both temporary and permanent occlusion of the arteries. A cannula carries an imaging device and a member which will easily penetrate tissue, the member including a device which partially or completely, and temporarily or permanently, occludes a uterine artery.

The invention relates to a manufacture method for a traditional Chinese medicine moxa stick with the efficacy of warming the uterus for dispelling cold. The traditional Chinese medicine moxa stick is prepared from the following raw materials in percentage by weight: 70-85% of three-year aged moxa floss and 30-15% of traditional Chinese medicine powder, wherein the traditional Chinese medicine powder comprises the following components in weight proportion: 3-5 g of angelica sinensis, 3-7 g of white paeony root, 3-7 g of salvia miltiorrhiza, 3-5 g of ligusticum wallichii, 3-5 g of carthamus tinctorius, 3-7 g of cyperus rotundus, 3-7 g of peach seed, 3-7 g of achyranthes bidentata, 3-7 g of leonurus artemisia, 3-7 g of rhizoma corydalis and 3-7 g of cassia twig. The manufacture method comprises the following steps: respectively weighing traditional Chinese medicines according to the weight proportion, smashing the traditional Chinese medicines, screening the smashed traditional Chinese medicines through a 100-mesh sieve, mixing the powders into the traditional Chinese medicine powder, and mixing the traditional Chinese medicine powder into the moxa floss according to the weight proportion so as to obtain the traditional Chinese medicine moxa stick. Targeted acupoints are selected to be subjected to moxibustion, so that the traditional Chinese medicine moxa stick is highly targeted, and especially can be used for conditioning, prevention and treatment for females with cold hands and feet, intolerance of cold, sensation of chill, soreness of waist, weakness, irregular menstruation, dysmenorrheal, hysteromyoma, ovarian cyst, cold in uterus, infertility and other symptoms.

A high-power ultrasound heating applicator for minimally-invasive thermal treatment of uterine fibroids or myomas. High-intensity interstitial ultrasound, applied with minimally-invasive laparoscopic or hysteroscopic procedures, is used to effectively treat fibroids within the myometrium in lieu of major surgery. The applicators are configured with high-power capabilities and thermal penetration to treat large volumes of fibroid tissue (>70 cm3) in short treatment times (3-20 minutes), while maintaining three-dimensional control of energy delivery to thermally destroy the target volume.

A medicament for the preventive and / or therapeutic treatment of allergic diseases and / or endometriosis and / or hysteromyoma which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substitutents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substitutents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

The invention discloses a traditional Chinese medicine composition for treating the symptoms of qi stasis, blood stasis, myoma and cyst and a preparation method. The traditional Chinese medicine composition mainly comprises the following raw materials of medicines: tangerine peel, immature bitter orange, rosa banksiae, rhizoma cyperi, TurmericRoot-tuber, medicated leaven, Chinese eaglewood, radix linderae, toosendan fruit, fructus citri sarcodactylis, malt, hawthorn, rhizoma ligustici wallichii, radix salviae miltiorrhizae, peach kernel, safflower, rhizoma sparganii, rhizoma zedoariae, scaly anteater, carapax amydae, tortoise plastron, semen raphani, green tangerine peel, radix aristolochiae, longstamen onion bulb, citron, scorched areca, dried ginger, corydalis tuber, curcuma, trogopterus dung, motherwort, spatholobus stem, logwood, draconis sanguis, red peony root, white peony root, angelica and the like. The traditional Chinese medicine composition can be prepared into any common oral preparation according to a conventional traditional Chinese medicine preparation method. The invention can obviously improve the physical signs of the whole bodies of patients with the symptoms of qi stasis, blood stasis, myoma and cyst, regulates the viscera functions of the patients, regulates the circulation of the qi and the blood of an organism, removes the qi stasis and the blood stasis, eliminates lumps, calms down the stasis and has definite clinical curative effect, obvious curative effect and quick acting. As basically adopting medicine-food homologous medicines specified by the dispensatory of China for combination, the traditional Chinese medicine composition has the advantages of low cost, no toxic or side effect basically and the like.

The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, and magnesium stearate; or can contain microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, povidone, and magnesium stearate. The compositions are useful in contraception and hormone replacement therapy and in the treatment and / or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefore Additional uses include stimulation of food intake.

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.

A gonadotropin-releasing hormone antagonistic composition, which comprises an optionally substituted condensed-bicyclic compound consisting of a homo or hetero 5 to 7 membered ring and a homo or hetero 5 to 7 membered ring is effective as a propylactic or therapeutic agent for the prevention or treatment of several hormone dependent diseases, for example, a sex hormone dependent cancer (e.g. prostatic cancer, cancer of uterine cervix, breast cancer, pituitary adenoma), benign prostatic hypertrophy, myoma of the uterus, endometriosis, precocious puberty, amenorrhea, premenstrual syndrome, polycystic ovary syndrome and acne vulgaris; is effective as a fertility controlling agent in both sexes (e.g. a pregnancy controlling agent and a menstrual cycle controlling agent); can be used as a contraceptive of male or female, as an ovulation-inducing agent of female; can be used as an infertility treating agent by using a rebound effect owing to a stoppage of administration thereof; is useful as modulating estrous cycles in animals in the field of animal husbandry, as an agent fro improving the quality of edible meat or promoting the growth of animals; is useful as an agent of spawning promotion in fish.

The present invention relates to a novel class of AKR1C3 inhibitors, to compositions containing them, to methods for their preparation, and to methods of use thereof. The AKR1C3 inhibitors may be useful in the treatment of, for example, prostate cancer, benign prostate hyperplasia (BPH), lung cancer, acne, seborrhea, hirsuitism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, uterine cancer, uterine fibroids, endometriosis, myeloma and leiomyoma.

This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and / or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

A medicament for the preventive and / or therapeutic treatment of allergic diseases and / or endometriosis and / or hysteromyoma which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof:wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substitutents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substitutents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

The present invention provides a vaginally administrable tablet useful for treating leiomyomata, leiomyoma, myoma, uterine fibroids, endometriosis, adenomyosis and other related disorders. The tablet comprises mifepristone, at least one non-effervescent excipient or diluent, and at least one effervescent excipient.